Small Molecule Inhibitors Targeting HIV‐1 Reverse Transcriptase Dimerization

The enzymatic activities of human immunodeficiency virus type 1 (HIV‐1) reverse transcriptase (RT) are strictly correlated with the dimeric forms of this vital retroviral enzyme. Accordingly, the development of inhibitors targeting the dimerization of RT represents a promising alternative antiviral strategy. Based on mutational studies, we applied a structure‐based ligand design approach generating pharmacophoric models of the large subunit connection subdomain to possibly identify small molecules from the ASINEX database, which might interfere with the RT subunit interaction. Docking studies of the selected compounds identified several candidates, which were initially tested in an in vitro subunit association assay. One of these molecules (MAS0) strongly reduced the association of the two RT subunits p51 and p66. Most notably, the compound simultaneously inhibited both the polymerase as well as the RNase H activity of the retroviral enzyme, following preincubation with t1/2 of about 2 h, indicative of a slow isomerization step. This step most probably represents a shift of the RT dimer equilibrium from an active to an inactive conformation. Taken together, to the best of our knowledge, this study represents the first successful rational screen for a small molecule HIV RT dimerization inhibitor, which may serve as attractive hit compound for the development of novel therapeutic agents.

[1]  P. Kollman,et al.  An approach to computing electrostatic charges for molecules , 1984 .

[2]  Eamonn F. Healy,et al.  Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model , 1985 .

[3]  P. Goodford.  A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[4]  H. Bujard,et al.  Subregions of a conserved part of the HIV gp41 transmembrane protein are differentially recognized by antibodies of infected individuals. , 1986, The EMBO journal.

[5]  G. A. Petersson,et al.  A complete basis set model chemistry. I. The total energies of closed‐shell atoms and hydrides of the first‐row elements , 1988 .

[6]  R. Wade,et al.  New hydrogen-bond potentials for use in determining energetically favorable binding sites on molecules of known structure. , 1989, Journal of medicinal chemistry.

[7]  R. Goody,et al.  Co-expression of the subunits of the heterodimer of HIV-1 reverse transcriptase in Escherichia coli. , 1989, The Journal of biological chemistry.

[8]  R. Goody,et al.  Dimerization of human immunodeficiency virus type 1 reverse transcriptase. A target for chemotherapeutic intervention. , 1990, The Journal of biological chemistry.

[9]  P. Kollman,et al.  Atomic charges derived from semiempirical methods , 1990 .

[10]  Erik De Clercq,et al.  Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives , 1990, Nature.

[11]  R. Goody,et al.  Expression of the heterodimeric form of human immunodeficiency virus type 2 reverse transcriptase in Escherichia coli and characterization of the enzyme. , 1991, The Journal of biological chemistry.

[12]  T. Naas,et al.  Subunit‐selective mutagenesis indicates minimal polymerase activity in heterodimer‐associated p51 HIV‐1 reverse transcriptase. , 1991, The EMBO journal.

[13]  T. Steitz,et al.  Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. , 1992, Science.

[14]  R. Goody,et al.  RNase H activity of HIV reverse transcriptases is confined exclusively to the dimeric forms , 1992, FEBS letters.

[15]  R. Goody,et al.  Structure-function relationships of HIV-1 reverse transcriptase determined using monoclonal antibodies. , 1992, The Journal of biological chemistry.

[16]  R. Goody,et al.  Characterization of the dimerization process of HIV‐1 reverse transcriptase heterodimer using intrinsic protein fluorescence , 1993, FEBS letters.

[17]  T. Steitz,et al.  Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[18]  R. Goody,et al.  Inhibition of human immunodeficiency virus type 1 reverse transcriptase dimerization using synthetic peptides derived from the connection domain. , 1994, The Journal of biological chemistry.

[19]  G. Deléage,et al.  Dimerization kinetics of HIV-1 and HIV-2 reverse transcriptase: a two step process. , 1995, Journal of molecular biology.

[20]  R. Goody,et al.  Conformational stability of dimeric HIV-1 and HIV-2 reverse transcriptases. , 1995, Biochemistry.

[21]  D. Stuart,et al.  High resolution structures of HIV-1 RT from four RT-inhibitor complexes. , 1996 .

[22]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[23]  S. Thrall,et al.  Kinetic Analysis of Four HIV-1 Reverse Transcriptase Enzymes Mutated in the Primer Grip Region of p66 , 1997, The Journal of Biological Chemistry.

[24]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998 .

[25]  Alexander D. MacKerell,et al.  All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.

[26]  Laxmikant V. Kale,et al.  NAMD2: Greater Scalability for Parallel Molecular Dynamics , 1999 .

[27]  Roger S. Goody,et al.  A New Potent HIV-1 Reverse Transcriptase Inhibitor , 1999, The Journal of Biological Chemistry.

[28]  M. Morris,et al.  The thumb domain of the P51-subunit is essential for activation of HIV reverse transcriptase. , 1999, Biochemistry.

[29]  J. Balzarini,et al.  Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro[4"-amino-2",2" -dioxo-1",2" -oxathiole-5",3'-[2', 5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]]]-3-ethylthy mine. , 2000, Biochemistry.

[30]  C. Lipinski.  Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[31]  H. Steinhoff,et al.  Temperature-dependent equilibrium between the open and closed conformation of the p66 subunit of HIV-1 reverse transcriptase revealed by site-directed spin labelling. , 2000, Journal of molecular biology.

[32]  B. Wöhrl,et al.  Asymmetric Subunit Organization of Heterodimeric Rous Sarcoma Virus Reverse Transcriptase αβ: Localization of the Polymerase and RNase H Active Sites in the α Subunit , 2000, Journal of Virology.

[33]  S. Sarafianos,et al.  Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[34]  D. Stuart,et al.  Structure of HIV-2 reverse transcriptase at 2.35-Å resolution and the mechanism of resistance to non-nucleoside inhibitors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[35]  N. Sluis-Cremer,et al.  Destabilization of the HIV-1 reverse transcriptase dimer upon interaction with N-acyl hydrazone inhibitors. , 2002, Molecular pharmacology.

[36]  S. Goff,et al.  Role of residues in the tryptophan repeat motif for HIV-1 reverse transcriptase dimerization. , 2003, Journal of molecular biology.

[37]  T. Berg.  Modulation von Protein‐Protein‐Wechselwirkungen mit niedermolekularen organischen Molekülen , 2003 .

[38]  T. Berg.  Modulation of protein-protein interactions with small organic molecules. , 2003, Angewandte Chemie.

[39]  C. Isel,et al.  Nucleoside and nucleotide inhibitors of HIV-1 replication , 2006, Cellular and Molecular Life Sciences CMLS.

[40]  P. Rothwell,et al.  Insight into the mechanism of a peptide inhibitor of HIV reverse transcriptase dimerization. , 2005, Biochemistry.

[41]  J. Kappes,et al.  Identification of amino acid residues in the human immunodeficiency virus type-1 reverse transcriptase tryptophan-repeat motif that are required for subunit interaction using infectious virions. , 2005, Journal of molecular biology.

[42]  S. de Castro,et al.  TSAO derivatives, inhibitors of HIV-1 reverse transcriptase dimerization: recent progress. , 2006, Current pharmaceutical design.

[43]  F. Gago,et al.  Dimerization inhibitors of HIV-1 reverse transcriptase, protease and integrase: a single mode of inhibition for the three HIV enzymes? , 2006, Antiviral research.

[44]  N. Sluis-Cremer,et al.  Dimerization of human immunodeficiency virus type 1 reverse transcriptase as an antiviral target. , 2006, Current pharmaceutical design.